Innate Pharma【IPHA】銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

3.00

買値

2.89

売値

3.05

出来高

13,593,143

1.47 日の範囲 3.5107

0.00 52 週間の範囲 0.00

時価総額

241.36M

前日終値

1.55

始値

1.50

時刻

最終取引時間

財務取引量

US$ 32,049,169

VWAP

2.3577

平均取引量 (3 か月)

発行済株式数

80,453,282

配当利回り

PER

-20.19

1 株当たり利益 (EPS)

-0.09

歳入

61.64M

純利益

-7.57M

Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therap... Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, avdoralimab, and others. 詳細を表示

セクター

Biological Pds,ex Diagnstics

業界

Biological Pds,ex Diagnstics

ウェブサイト

www.innate-pharma.com

本社

Marseille, Bouches-du-rhone, Fra

設立

Innate Pharma SA is listed in the Biological Pds,ex Diagnstics sector of the ナスダック市場 with ticker IPHA. The last closing price for Innate Pharma was US$1.55. Over the last year, Innate Pharma shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Innate Pharma currently has 80,453,282 shares in issue. The market capitalisation of Innate Pharma is US$124.70 million. Innate Pharma has a price to earnings ratio (PE ratio) of -20.19.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Innate Pharma présente à l’ASH 2024 des données de l’étude de Phase 2 TELLOMAK sur l’amélioration de la qualité de vie chez des patients atteints de lymphomes T cutanés

Les résultats mettent en évidence des signes précoces prometteurs selon lesquels lacutamab pourrait aider à soulager certains des symptômes les plus éprouvants des lymphomes T cutanés...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

Innate will receive 3m USD upfront plus up to 4.9m USD in conditional tranched investments from The Institute for Follicular Lymphoma Innovation (IFLI) Patients with R/R Follicular Lymphoma will...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
WKEYWISeKey International Holdings AG	US$ 7.84 (139.02%)	75.53M
IPHAInnate Pharma SA	US$ 3.00 (93.55%)	13.59M
AVLDirexion Daily AVGO Bull 2X Shares	US$ 33.67 (48.92%)	658.55k
LOOPLoop Industries Inc	US$ 1.8092 (47.09%)	82.56M
AVGXDefiance Daily Target 2X Long AVGO ETF	US$ 31.49 (46.67%)	3.55M
RPTXRepare Therapeutics Inc	US$ 1.765 (-55.54%)	4.7M
INOInovio Pharmaceuticals Inc New	US$ 2.31 (-38.56%)	9.86M
XXII22nd Century Group Inc	US$ 0.048 (-34.69%)	42.23M
FLGCFlora Growth Corporation	US$ 1.30 (-34.34%)	4.14M
WTOUTime Limited	US$ 0.281 (-32.74%)	3.79M
NVDANVIDIA Corporation	US$ 134.25 (-2.25%)	231.23M
SOUNSoundHound AI Inc	US$ 16.905 (23.66%)	159.56M
TRUGTruGolf Holdings Inc	US$ 0.6794 (30.93%)	141.89M
RGTIRigetti Computing Inc	US$ 7.155 (19.85%)	124.45M
AVGOBroadcom Inc	US$ 224.80 (24.43%)	121.33M